KCT0001947已完成未知
Comparison of the efficacy and safety of cilnidipine 10mg/valsartan 160mg combination therapy, cilnidipine 5mg/valsartan 160mg combination therapy and valsartan 160mg monotherapy in hypertensive patients inadequately controlled with valsartan 160mg monotherapy : a multicenter, randomized, double blind phase III study
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 入组人数
- 279
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional Study
入排标准
- 年龄范围
- 20(Year) 至 o Limit（—）
- 性别
- All
入选标准
- •1) 20 years old or more adult Men and Ladies
- •2) who meet the following criteria to patients diagnosed with essential hypertension
- •- If screening before treated with anti-hypertensive drug
- •- In the case of naïve patients (patients without a history of antihypertensive drug administration for more than 30 days) sit Diastoloc Blood Pressure = 95mmHg screening point
- •3) valsartan 160mg monotherapy (run-in period) 4 weeks patients (110mmHg> sit Diastoloc Blood Pressure = 90mmHg seems insufficient reaction)
- •4) sufficient understanding of the agreement and the parties agree in writing
排除标准
- •1) screening blood pressure measurement of blood pressure difference between each measured three times the average of three blood pressure measurements after eight loci with high DBP(Diastolic Blood Pressure) - both arms over each sit SBP(Systolic blood pressure) 20mmHg or sit DBP(Diastolic Blood Pressure) 10mmHg or more patients
- •(* DBP(Diastolic Blood Pressure) SBP(Systolic blood pressure) is to select the high-arm when the same. If the same DBP(Diastolic Blood Pressure) and SBP(Systolic blood pressure), and select the right arm)
- •2) the average time patients randomized in a sit SBP(Systolic blood pressure)=180mmHg
- •3) patients with a history of hypersensitivity reactions to drugs based on Dihydropyridine
- •4) Patients with a history of hypersensitivity to the drug in the angiotensin II receptor blocker system
- •5) Patients with secondary hypertension or secondary hypertension is suspected (aortic coarctation, and primary aldosteronism, renal artery stenosis, Cushing's disease, polycystic kidney disease, renal hypertension, pheochromocytoma, etc.)
- •6) Patients expect other antihypertensive drugs outside of clinical medicine during the test period (ACE(Angiotensin-Converting enzyme) inhibitor, ß-blockers, calcium antagonists, angiotensin II receptor blocker, diuretics, a-blockers, vasodilators, etc.)
- •7) The second type does not type 1 diabetes patients and control patients with diabetes (HbA1c=9 If)
- •8)- Severe heart disease {heart failure (NYHA(New york Heart Association) class III and IV)},
- •- A person who is newly diagnosed disease for the last 6 months down,: ischemic heart disease (angina pectoris and myocardial infarction), peripheral vascular disease
- •- Recently I received treatment within 6 months following the corresponding character: percutaneous transluminal coronary angioplasty, coronary artery bypass grafting (CABG)
- •9) severe atrial fibrillation, atrial flutter, or the party who has the serious arrhythmia with ventricular tachycardia
- •10) Severe cerebrovascular disorders (stroke within 6 months etc.)
- •11) Now with hypertrophic obstructive cardiomyopathy, severe obstructive coronary artery disease, aortic stenosis, clinically meaningful aortic or mitral stenosis on
- •12) Now with a history of shock, fainting, consciousness disorders of the blood pressure
- •13) hyperkalemia patient, or sodium patient body fluid shortage
- •14) Patients with known moderate or malignant retinopathy
- •15) or hereditary angioedema, ACE(Angiotensin-Converting enzyme) inhibitor or ARB(Angiotensin II Receptor Blocker) therapy when the party with a history of angioedema
- •16) patients with severe liver failure, liver cirrhosis or biliary obstruction, cholestasis patients
- •17) Clinically significant hematologic findings seen more than 2mg / dl kidney disease (serum creatinine levels or hemodialysis patients) or liver (ALT or AST more than 2 times the upper limit of normal) patients
- •18) If a surgical or medical conditions which can significantly change the absorption, distribution, metabolism and excretion of a drug which is either of the following (but not limited to): gastrectomy, upper small intestine anastomosis (gastro-enterostomy ) or intestinal resection (bowel resection), bypass the gastrointestinal tract, gastrointestinal stapled (stapling), or gastrointestinal banding (banding) major gastrointestinal surgical history, history of active inflammatory bowel syndrome within the previous 12 months of the current or the like. Currently there are active gastritis, ulc
研究者
相似试验
已完成
不适用
Comparison of the effects of cilnidipine and benidipine on urinary excretions of albumin and type-IV collagen in Japanese hypertensive type-2 diabetic patients with nephropathy.hypertensive type-2 diabetic patients with nephropathyJPRN-UMIN000005384Akita University Garduate School of Medicine, Department of Endocrinology, Diabetes and Geriatric Medicine40
招募中
4 期
Comparative study of chemotherapy in esophagus carcinoma.CTRI/2014/04/004516Tata Memorial Hospital350
已完成
不适用
Comparative evaluation of the effect of Clonidine and Atenolol premedication on hemodynamic effects and Propofol dose requirement in patients undergoing ERCP under monitored anesthesia care: a double blind, randomized, placebo controlled study.CTRI/2012/05/002643SGPGI114
尚未招募
2 期
Role of pippali churna orally with udumber tail pichu in management of kaphaj yonivyapadCTRI/2021/01/030276Dr Jayashree Abhijit Sawashe
已完成
不适用
Comparison of effects of cilnidipine and azelnidipine on blood pressure and urinary albumin excretion in type 2 diabetics with hypertensioType 2 diabetic patientsJPRN-UMIN000007201Juntendo University Graduate School of Medicine20